Intracerebral infusion of DOPAC decreases striatal dopamine

Ramin Shiekhattar, M. Behnam Ghasemzadeh, Ralph N. Adams

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


The purpose of this study was to determine whether elevated levels of 3,4-dihydroxyphenylacetic acid (DOPAC), the major metabolite of dopamine (DA) in the brain, could decrease the DA content in the striatum. Levels of DA were determined by high pressure liquid chromatography with electrochemical detection (HPLCEC) in the striatum of male rats 24 h following a single intracerebral administration of DOPAC into the right striatum. DOPAC at 16.8 μg reduced the DA content of the infused side by 17%, p = 0.01. In contrast, infusion of 1.68 Mg of DOPAC or the vehicle had no effect on striatal DA levels. Coapplication of the antioxidant, ascorbic acid, at 0.2 mg/ml with 16.8 Mg of DOPAC prevented the decrease in DA content. Furthermore, infusion of 18.2 μg of homovanillic acid (HVA), the product of DOPAC methylation, had no effect on striatal DA. These results indicate that DOPAC may undergo autoxidation in vivo to produce neurotoxic species which may result in reduction of striatal DA. Formation of such an autoxidation product(s) of endogenous DOPAC was verified in the extracellular fluid of striatal slices in vitro.

Original languageEnglish (US)
Pages (from-to)891-896
Number of pages6
JournalBrain Research Bulletin
Issue number6
StatePublished - Dec 1992
Externally publishedYes


  • Autoxidation
  • Caudate
  • Free radicals
  • Parkinson's disease
  • Quinones
  • Toxicity

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'Intracerebral infusion of DOPAC decreases striatal dopamine'. Together they form a unique fingerprint.

Cite this